M. GloriaMancuso

M. Gloria Mancuso serves as a Purchasing Agent for the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, where she plays a pivotal role in executing mission-critical acquisitions that support scientific research and public health initiatives. She manages the full lifecycle of procurement actions—from market research and solicitation development to contract award and administration—ensuring compliance with federal acquisition regulations and NIDA’s strategic objectives. Her portfolio primarily encompasses professional services, laboratory support, and specialized manufacturing needs aligned with addiction science and biomedical innovation. While specific contractor names are not publicly disclosed, Mancuso maintains a broad network of vendor partnerships spanning consulting firms, biomanufacturers, and technical service providers. Her procurement patterns reflect a preference for competitive, open-market opportunities, with consistent engagement with both large and small businesses that demonstrate technical proficiency in highly regulated scientific domains. She prioritizes clear performance metrics and contract deliverables, fostering transparent, results-driven vendor relationships. Mancuso’s set-aside preferences reveal a strong but measured commitment to small business participation. Approximately 11.7% of her acquisitions are reserved for small businesses, including 10.4% under Total Small Business Set-Asides and 1.3% under 8(a) competed programs. While the majority of her contracts (88.3%) are awarded without set-asides, her consistent use of socioeconomic programs demonstrates alignment with federal goals to expand opportunity for disadvantaged and emerging businesses in the biomedical sector. Her procurement focus centers on NAICS codes related to management consulting services (541611, 541618), biological product manufacturing (325414), and miscellaneous chemical product manufacturing (325998), with notable activity in facility and laboratory support services (811219). These reflect NIDA’s need for scientific administration, research infrastructure, and specialized chemical and biological materials essential to drug abuse studies and therapeutic development. Her expertise lies in navigating complex regulatory environments to procure high-integrity goods and services for federally funded biomedical research.